08:57 AM EDT, 04/09/2024 (MT Newswires) -- Pfizer ( PFE ) said Tuesday that its current pivotal phase 3 trial of Abrysvo against placebo in participants aged 18 to 59 years met primary endpoints.

The patients were at an increased risk of developing respiratory syncytial virus-associated lower respiratory tract disease, the company said.

In the trial, patients attained at least a four-fold increase in serum neutralizing titers for respiratory syncytial virus-A and respiratory syncytial virus-B after one month of Abrysvo as compared with pre-vaccination, according to the company.

Pfizer ( PFE ) also said Abrysvo was "well-tolerated" during the trial, while safety results were also "consistent" from prior Abrysvo studies.

The company plans to share data with regulatory authorities for approval of Abrysvo in adults 18 to 59 years of age.

Price: 26.68, Change: +0.1, Percent Change: +0.38